| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Antigen, T-Cell | 15 | 2023 | 1135 | 2.950 |
Why?
|
| T-Lymphocytes | 26 | 2024 | 3945 | 2.950 |
Why?
|
| Immunotherapy, Adoptive | 23 | 2024 | 1854 | 2.840 |
Why?
|
| Antigens, CD19 | 14 | 2024 | 585 | 2.560 |
Why?
|
| Lymphoma | 10 | 2024 | 1516 | 2.010 |
Why?
|
| Hodgkin Disease | 6 | 2023 | 1485 | 1.640 |
Why?
|
| Ki-1 Antigen | 3 | 2023 | 186 | 1.380 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2018 | 1068 | 1.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 5 | 2023 | 382 | 1.040 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2024 | 37 | 0.910 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 367 | 0.880 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2024 | 7055 | 0.860 |
Why?
|
| Immunotherapy | 7 | 2023 | 3561 | 0.760 |
Why?
|
| Drug Approval | 1 | 2021 | 173 | 0.680 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2019 | 1019 | 0.650 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 69 | 0.530 |
Why?
|
| Vidarabine | 3 | 2020 | 1384 | 0.490 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1956 | 0.490 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 67 | 0.480 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 551 | 0.460 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2016 | 2488 | 0.460 |
Why?
|
| Caspase 9 | 2 | 2014 | 187 | 0.450 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 64 | 0.430 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 389 | 0.420 |
Why?
|
| Cyclophosphamide | 4 | 2020 | 3245 | 0.420 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 174 | 0.410 |
Why?
|
| Genetic Therapy | 5 | 2022 | 1715 | 0.410 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 148 | 0.400 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2006 | 1362 | 0.400 |
Why?
|
| Retroviridae | 4 | 2022 | 372 | 0.390 |
Why?
|
| Antilymphocyte Serum | 1 | 2012 | 236 | 0.380 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 255 | 0.370 |
Why?
|
| Anemia, Aplastic | 1 | 2012 | 232 | 0.350 |
Why?
|
| Antigens, CD | 1 | 2015 | 1420 | 0.350 |
Why?
|
| Epitopes | 3 | 2020 | 699 | 0.350 |
Why?
|
| Humans | 61 | 2024 | 270637 | 0.350 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2014 | 206 | 0.330 |
Why?
|
| Transplantation Conditioning | 3 | 2022 | 2374 | 0.310 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 5144 | 0.310 |
Why?
|
| Antigens, Neoplasm | 5 | 2022 | 1581 | 0.310 |
Why?
|
| Transplantation, Homologous | 9 | 2024 | 3048 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 10404 | 0.300 |
Why?
|
| Herpesvirus 4, Human | 8 | 2023 | 959 | 0.300 |
Why?
|
| Virus Diseases | 2 | 2023 | 375 | 0.290 |
Why?
|
| Hepatitis B | 1 | 2010 | 273 | 0.280 |
Why?
|
| Antiviral Agents | 4 | 2024 | 1243 | 0.280 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2018 | 1623 | 0.270 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 316 | 0.270 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 1754 | 0.270 |
Why?
|
| Lymphocyte Activation | 6 | 2019 | 1719 | 0.270 |
Why?
|
| CD28 Antigens | 3 | 2019 | 212 | 0.260 |
Why?
|
| Hepacivirus | 1 | 2009 | 423 | 0.260 |
Why?
|
| Immunophenotyping | 4 | 2019 | 1723 | 0.250 |
Why?
|
| Repressor Proteins | 1 | 2013 | 1715 | 0.240 |
Why?
|
| Transplantation, Autologous | 4 | 2022 | 2073 | 0.240 |
Why?
|
| Alemtuzumab | 1 | 2024 | 213 | 0.230 |
Why?
|
| Neoplasms | 5 | 2022 | 15949 | 0.230 |
Why?
|
| Graft vs Host Disease | 4 | 2024 | 2811 | 0.220 |
Why?
|
| Immunologic Memory | 3 | 2019 | 376 | 0.210 |
Why?
|
| Tumor Escape | 2 | 2018 | 247 | 0.210 |
Why?
|
| Multiple Myeloma | 3 | 2021 | 2336 | 0.210 |
Why?
|
| Sequence Analysis, Protein | 1 | 2003 | 80 | 0.210 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 273 | 0.210 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2014 | 63 | 0.210 |
Why?
|
| Salvage Therapy | 2 | 2021 | 2124 | 0.210 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 191 | 0.200 |
Why?
|
| Mice, SCID | 4 | 2015 | 1825 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 4468 | 0.200 |
Why?
|
| Cell Separation | 2 | 2004 | 606 | 0.200 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 266 | 0.200 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 327 | 0.190 |
Why?
|
| Adult | 19 | 2024 | 82023 | 0.190 |
Why?
|
| Genetic Engineering | 2 | 2020 | 288 | 0.190 |
Why?
|
| Young Adult | 10 | 2024 | 22238 | 0.190 |
Why?
|
| Middle Aged | 19 | 2024 | 90495 | 0.190 |
Why?
|
| Treatment Outcome | 12 | 2018 | 33840 | 0.190 |
Why?
|
| Leukemia | 2 | 2024 | 1719 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 2903 | 0.180 |
Why?
|
| Basigin | 1 | 2020 | 22 | 0.180 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 107 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2006 | 3463 | 0.180 |
Why?
|
| Animals | 21 | 2020 | 61340 | 0.180 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 223 | 0.180 |
Why?
|
| Lymphocyte Transfusion | 1 | 2021 | 174 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 491 | 0.180 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 14638 | 0.180 |
Why?
|
| Gene Transfer Techniques | 2 | 2015 | 800 | 0.170 |
Why?
|
| Stem Cells | 2 | 2006 | 1212 | 0.170 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 123 | 0.170 |
Why?
|
| Male | 23 | 2024 | 128446 | 0.170 |
Why?
|
| Neovascularization, Physiologic | 3 | 2006 | 341 | 0.170 |
Why?
|
| Gene Frequency | 1 | 2003 | 1246 | 0.170 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 9053 | 0.170 |
Why?
|
| Virus Activation | 2 | 2012 | 241 | 0.170 |
Why?
|
| Quinazolines | 1 | 2024 | 956 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 322 | 0.170 |
Why?
|
| Aged | 14 | 2024 | 73579 | 0.170 |
Why?
|
| Female | 23 | 2024 | 148834 | 0.160 |
Why?
|
| SOXC Transcription Factors | 1 | 2019 | 58 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2021 | 3840 | 0.160 |
Why?
|
| Virus Replication | 1 | 2022 | 762 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 2 | 2019 | 930 | 0.160 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 443 | 0.160 |
Why?
|
| Bone Marrow | 3 | 2021 | 2440 | 0.160 |
Why?
|
| Mice | 16 | 2020 | 35414 | 0.150 |
Why?
|
| Cells, Cultured | 7 | 2018 | 5657 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2006 | 2157 | 0.150 |
Why?
|
| Cell Engineering | 1 | 2017 | 35 | 0.150 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 27 | 0.150 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 1420 | 0.150 |
Why?
|
| DNA Viruses | 1 | 2017 | 45 | 0.140 |
Why?
|
| Viral Matrix Proteins | 2 | 2018 | 176 | 0.140 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 965 | 0.140 |
Why?
|
| Cytomegalovirus | 5 | 2024 | 494 | 0.140 |
Why?
|
| Glenoid Cavity | 1 | 2016 | 4 | 0.140 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 431 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 587 | 0.140 |
Why?
|
| Blood Platelets | 2 | 2019 | 675 | 0.140 |
Why?
|
| Cell Differentiation | 5 | 2019 | 4105 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 81 | 0.130 |
Why?
|
| Mitochondria | 1 | 2003 | 1292 | 0.130 |
Why?
|
| Shoulder Joint | 1 | 2016 | 63 | 0.130 |
Why?
|
| Genetic Vectors | 5 | 2022 | 1837 | 0.130 |
Why?
|
| Joint Instability | 1 | 2016 | 78 | 0.130 |
Why?
|
| Cloning, Molecular | 3 | 2014 | 1406 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 424 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 4102 | 0.120 |
Why?
|
| Recurrence | 5 | 2021 | 4878 | 0.120 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2014 | 4 | 0.120 |
Why?
|
| Adolescent | 9 | 2024 | 32687 | 0.120 |
Why?
|
| Cell Proliferation | 8 | 2019 | 7232 | 0.120 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 14878 | 0.120 |
Why?
|
| Wound Healing | 1 | 2019 | 771 | 0.120 |
Why?
|
| Calpain | 1 | 2014 | 69 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3929 | 0.110 |
Why?
|
| Interleukin-7 | 1 | 2014 | 92 | 0.110 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2014 | 163 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2017 | 316 | 0.110 |
Why?
|
| Adult Stem Cells | 1 | 2014 | 73 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 590 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2006 | 1072 | 0.110 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 1493 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 1420 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 770 | 0.110 |
Why?
|
| Sequence Alignment | 3 | 2006 | 866 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 1503 | 0.110 |
Why?
|
| Flow Cytometry | 3 | 2015 | 3040 | 0.110 |
Why?
|
| Interleukin-15 | 1 | 2014 | 191 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2014 | 1801 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2014 | 355 | 0.100 |
Why?
|
| Hematopoiesis | 3 | 2023 | 600 | 0.100 |
Why?
|
| Remission Induction | 2 | 2016 | 3658 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 39 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 881 | 0.100 |
Why?
|
| Adenoviridae | 5 | 2019 | 1490 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 5053 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 690 | 0.100 |
Why?
|
| Pyrazines | 1 | 2014 | 511 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1195 | 0.090 |
Why?
|
| Retrospective Studies | 8 | 2024 | 39954 | 0.090 |
Why?
|
| Interleukin-2 | 1 | 2014 | 889 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2360 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 7273 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 3582 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2015 | 2087 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 1656 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 7317 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2010 | 6231 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 704 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 2 | 2006 | 1587 | 0.080 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 696 | 0.080 |
Why?
|
| Dimerization | 2 | 2014 | 310 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2015 | 3567 | 0.080 |
Why?
|
| Biomarkers | 3 | 2022 | 5048 | 0.080 |
Why?
|
| Cell Culture Techniques | 2 | 2019 | 573 | 0.080 |
Why?
|
| Gout | 1 | 2011 | 146 | 0.080 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 718 | 0.080 |
Why?
|
| Child | 8 | 2024 | 30558 | 0.080 |
Why?
|
| Cytokines | 2 | 2019 | 2803 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 3155 | 0.070 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2007 | 69 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 2191 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 1044 | 0.070 |
Why?
|
| T-Cell Antigen Receptor Specificity | 2 | 2021 | 92 | 0.070 |
Why?
|
| Thrombospondins | 1 | 2006 | 21 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2396 | 0.070 |
Why?
|
| United States | 2 | 2021 | 15813 | 0.070 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 4198 | 0.070 |
Why?
|
| Tissue Donors | 2 | 2021 | 819 | 0.070 |
Why?
|
| Ischemia | 2 | 2006 | 400 | 0.070 |
Why?
|
| Leishmania mexicana | 1 | 2006 | 5 | 0.070 |
Why?
|
| Spinal Cord Compression | 1 | 2007 | 167 | 0.070 |
Why?
|
| Disease Progression | 1 | 2017 | 6880 | 0.060 |
Why?
|
| Survival Rate | 2 | 2010 | 12528 | 0.060 |
Why?
|
| Histidine | 1 | 2005 | 96 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 16740 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2019 | 626 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2007 | 350 | 0.060 |
Why?
|
| Molecular Sequence Data | 4 | 2006 | 6638 | 0.060 |
Why?
|
| Receptor, TIE-2 | 1 | 2005 | 78 | 0.060 |
Why?
|
| DNA Primers | 2 | 2006 | 1489 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 709 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 999 | 0.060 |
Why?
|
| Acetates | 1 | 2024 | 118 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 6192 | 0.060 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 1162 | 0.060 |
Why?
|
| RNA Splicing | 1 | 2005 | 362 | 0.060 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2003 | 20 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 425 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2006 | 4532 | 0.060 |
Why?
|
| Circular Dichroism | 1 | 2003 | 106 | 0.060 |
Why?
|
| Solutions | 1 | 2003 | 109 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 1469 | 0.050 |
Why?
|
| Meningeal Neoplasms | 1 | 2007 | 473 | 0.050 |
Why?
|
| Apoptosis | 3 | 2014 | 7755 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 2477 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 4839 | 0.050 |
Why?
|
| Heparin | 1 | 2005 | 343 | 0.050 |
Why?
|
| X-Ray Diffraction | 1 | 2003 | 173 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2003 | 195 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2009 | 1104 | 0.050 |
Why?
|
| Restriction Mapping | 1 | 2003 | 326 | 0.050 |
Why?
|
| Telomerase | 1 | 2006 | 544 | 0.050 |
Why?
|
| Regeneration | 1 | 2005 | 283 | 0.050 |
Why?
|
| Protein Folding | 1 | 2003 | 297 | 0.050 |
Why?
|
| Spinal Neoplasms | 1 | 2007 | 671 | 0.050 |
Why?
|
| Immunological Synapses | 1 | 2022 | 40 | 0.050 |
Why?
|
| Cell Count | 1 | 2003 | 509 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 225 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 1903 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2003 | 285 | 0.050 |
Why?
|
| Cell Line | 2 | 2022 | 5313 | 0.050 |
Why?
|
| Cell Survival | 2 | 2019 | 3057 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2006 | 7047 | 0.050 |
Why?
|
| Benchmarking | 1 | 2003 | 276 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 146 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2003 | 1250 | 0.040 |
Why?
|
| Protein Structure, Secondary | 2 | 2014 | 337 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2006 | 1031 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 38 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 432 | 0.040 |
Why?
|
| Receptors, Odorant | 1 | 2019 | 47 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2003 | 698 | 0.040 |
Why?
|
| Neutropenia | 1 | 2024 | 1006 | 0.040 |
Why?
|
| Incidence | 1 | 2010 | 5814 | 0.040 |
Why?
|
| Antigens, Viral | 2 | 2012 | 495 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 686 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 871 | 0.040 |
Why?
|
| Melphalan | 1 | 2022 | 879 | 0.040 |
Why?
|
| Epidermis | 1 | 2019 | 197 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3054 | 0.040 |
Why?
|
| Antigens, CD7 | 1 | 2018 | 30 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1824 | 0.040 |
Why?
|
| Cell Division | 1 | 2003 | 2657 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2020 | 5692 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 365 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 481 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2019 | 293 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2003 | 1567 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 2986 | 0.040 |
Why?
|
| Lentivirus | 1 | 2018 | 165 | 0.040 |
Why?
|
| Gene Editing | 1 | 2019 | 229 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 429 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2018 | 274 | 0.040 |
Why?
|
| Hemiarthroplasty | 1 | 2016 | 4 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5582 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 191 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 523 | 0.030 |
Why?
|
| Base Sequence | 1 | 2003 | 5405 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 490 | 0.030 |
Why?
|
| Rituximab | 1 | 2022 | 1594 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 126 | 0.030 |
Why?
|
| Alleles | 1 | 2003 | 2597 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 114 | 0.030 |
Why?
|
| Thrombopoiesis | 2 | 2006 | 23 | 0.030 |
Why?
|
| Chemokines, CXC | 2 | 2006 | 124 | 0.030 |
Why?
|
| Chemokine CXCL12 | 2 | 2006 | 131 | 0.030 |
Why?
|
| Plasmids | 1 | 2018 | 923 | 0.030 |
Why?
|
| Homeostasis | 2 | 2014 | 925 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2014 | 1736 | 0.030 |
Why?
|
| Cytarabine | 1 | 2022 | 2014 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 17071 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 965 | 0.030 |
Why?
|
| Luciferases, Firefly | 1 | 2014 | 40 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 102 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 123 | 0.030 |
Why?
|
| Patient Selection | 1 | 2022 | 2029 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2014 | 92 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 5157 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 2014 | 68 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2014 | 271 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 97 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 598 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 887 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 551 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2012 | 60 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 485 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 686 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 493 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 12974 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 768 | 0.020 |
Why?
|
| Cell Movement | 1 | 2019 | 2468 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2014 | 487 | 0.020 |
Why?
|
| Colchicine | 1 | 2011 | 67 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 825 | 0.020 |
Why?
|
| Reoperation | 1 | 2016 | 1388 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1072 | 0.020 |
Why?
|
| Prognosis | 2 | 2021 | 22527 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2006 | 1648 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4493 | 0.020 |
Why?
|
| Phenotype | 2 | 2018 | 6502 | 0.020 |
Why?
|
| Aorta | 1 | 2014 | 666 | 0.020 |
Why?
|
| Allopurinol | 1 | 2011 | 84 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 3057 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2012 | 691 | 0.020 |
Why?
|
| Steroids | 1 | 2011 | 372 | 0.020 |
Why?
|
| Myocardium | 1 | 2014 | 1180 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 784 | 0.020 |
Why?
|
| Paraparesis | 1 | 2007 | 15 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 762 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 17849 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2007 | 55 | 0.020 |
Why?
|
| Prednisolone | 1 | 2007 | 134 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 15274 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 9278 | 0.020 |
Why?
|
| Hindlimb | 1 | 2006 | 109 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2006 | 51 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 4905 | 0.020 |
Why?
|
| Thrombopoietin | 1 | 2006 | 102 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 2491 | 0.020 |
Why?
|
| Stilbenes | 1 | 2006 | 86 | 0.020 |
Why?
|
| DNA, Protozoan | 1 | 2006 | 33 | 0.020 |
Why?
|
| Leishmania major | 1 | 2006 | 27 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2006 | 128 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 308 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 6396 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 818 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 121 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2005 | 56 | 0.020 |
Why?
|
| Heparitin Sulfate | 1 | 2005 | 54 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2005 | 20 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3606 | 0.020 |
Why?
|
| Chromosomes | 1 | 2006 | 325 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 276 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 783 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5417 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6255 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 628 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2005 | 389 | 0.010 |
Why?
|
| Vincristine | 1 | 2007 | 1582 | 0.010 |
Why?
|
| Phylogeny | 1 | 2006 | 854 | 0.010 |
Why?
|
| Texas | 1 | 2013 | 6445 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 2199 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 10268 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 866 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 2249 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5674 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 1990 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2007 | 3145 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 2313 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 1161 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 1057 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 1502 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 13406 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 1580 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 2134 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 1184 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 2560 | 0.010 |
Why?
|
| Computational Biology | 1 | 2004 | 1294 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2005 | 12033 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 31110 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 3328 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 6344 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 3186 | 0.010 |
Why?
|
| HIV Infections | 1 | 2007 | 2154 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 7786 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 15917 | 0.000 |
Why?
|